Efficacy analyses
The principal outcome was defined by ADAS-Cog11.Efficacy analyses (ADAS-Cog11 and CIBIC+) were performed in the modified intention-to-treat population (mITT, participants with at least one dose of neuroEPO plus or placebo and a baseline measurement based on randomized treatment).Secondary efficacy analyses (ADAS-Cog11, CIBIC+, GDS, MoCA, NPI, ADL, hippocampal volume, and brain perfusion) were performed in the per protocol population (PP, subjects who complied with the protocol sufficiently to ensure that these data would be likely to exhibit the effects of treatment according to the underlying scientific model).Goodness-of-fit to the normal distribution was evaluated using the Kolmogorov-Smirnov test. The variables used did not meet the above assumption. Therefore, they are summarized using the median, as well as the 95% confidence intervals for the differences with respect to the placebo group. Comparisons were made using Kruskal-Wallis test and Dunn test for multiple comparisons. With the qualitative variables, the dependency relationship regarding the treatment was studied using the chi-square test.It was planned that if the probability of the fulfilled the hypothesis at 24 weeks was small 